Consultation on the protection and enforcement of IP rights in third countries
Position Paper
25 Nov 2020
Healthcare, Intellectual property

The American Chamber of Commerce to the European Union (AmCham EU) welcomes the European Commission’s ongoing efforts to advance strong and balanced intellectual property rights (IPR) globally. Together with the EU Counterfeit and Piracy Watch List, the biannual report on the protection and enforcement of IPR in third countries is an important tool in assessing the scale and scope of the challenges being faced, and in determining where to focus the EU’s efforts. US businesses invested in and committed to Europe often rely on the appropriate legal frameworks in third countries regarding IPR. These US companies invest and innovate in a range of critical sectors, including life sciences, digital, audiovisual and consumer goods. Such innovations bring benefits to citizens, patients and consumers, as well as the broader economy – not just in Europe or the US, but across the globe.

We call upon the European Commission to strengthen its focus on securing sustainable improvements to the IP environment in third counties. The Commission’s work with third countries should include a focus on strengthening rules and technical capabilities of authorities, clear and measurable objectives in improving prosecution of bad actors, reduction of exported infringements and ease of resolving civil disputes between competitors. The mechanisms to support this may include further dialogue and engagement of third country governments and other stakeholders, technical programmes (eg, IP Key), negotiating ambitious IP provisions in EU Free Trade Agreements (FTAs), and critically the Commission’s new trade enforcement strategy, which strengthens the implementation and enforcement of EU trade policy, including for IP. In addition, we also encourage reinforcing existing collaborations, including with the US. AmCham EU stands ready to work with the European Commission in achieving those goals and in sharing insight on other countries and the IPR challenges faced by our companies globally.

Related items

Position Paper
11 Nov 2025

Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations

The Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) have created unworkable complexity for the medical devices industry, with dire consequences for European patients. To address these challenges, Members of the European Parliament (MEPs) or political groups can help address the unintended consequences of the current framework by tabling a Parliamentary Question that urges the European Commission to introduce targeted relief measures in parallel to a comprehensive revision of the MDR and IVDR. This would support the European Commission to implement short-term relief measures, in addition to the MDR/IVDR revision, that bolster efficiency, mitigate administrative bottlenecks and increase predictability in the regulatory processes. This would have an immediate impact on patient access and boost Europe’s innovation.

Healthcare
Read more
Read more about Advancing short-term improvements to the EU Medical Devices and In Vitro Diagnostic Regulations
Position Paper
7 Jul 2025

Critical Medicines Act: securing resilient and diversified supply chains for continuous access

The proposed Critical Medicines Act (CMA) offers a pivotal opportunity to strengthen the EU’s pharmaceutical resilience. By embracing global supply chain diversification, open trade and strategic international cooperation, the EU can reinforce access to essential medicines while preserving its competitiveness. However, to succeed, the CMA must steer clear of protectionist approaches that risk undermining the internal market and disrupting supply. Instead, it should promote pragmatic, market-driven solutions with strong industry involvement. Read our full position to explore how the EU can foster a stable, secure and innovation-friendly environment for medicines.

Healthcare
Read more
Read more about Critical Medicines Act: securing resilient and diversified supply chains for continuous access
Position Paper
25 May 2025

Consultation response: Revision of the Medical Devices and In Vitro Diagnostic Medical Devices Regulations

Healthcare
Read more
Read more about Consultation response: Revision of the Medical Devices and In Vitro Diagnostic Medical Devices Regulations